Lisata Therapeutics (NASDAQ:LSTA) Trading Up 2.5%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) shares were up 2.5% during mid-day trading on Thursday . The company traded as high as $2.86 and last traded at $2.85. Approximately 1,130 shares traded hands during trading, a decline of 92% from the average daily volume of 13,442 shares. The stock had previously closed at $2.78.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Lisata Therapeutics in a research note on Friday, March 1st.

Lisata Therapeutics Stock Down 5.3 %

The stock’s 50 day moving average is $3.03 and its two-hundred day moving average is $2.69. The company has a market capitalization of $22.44 million, a PE ratio of -1.05 and a beta of 1.04.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.20. On average, sell-side analysts predict that Lisata Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Institutional Trading of Lisata Therapeutics

A number of hedge funds have recently added to or reduced their stakes in LSTA. Dimensional Fund Advisors LP purchased a new stake in Lisata Therapeutics in the third quarter worth about $57,000. Citadel Advisors LLC bought a new position in Lisata Therapeutics in the second quarter worth about $64,000. State Street Corp bought a new position in Lisata Therapeutics in the third quarter worth about $66,000. BlackRock Inc. bought a new position in Lisata Therapeutics in the third quarter worth about $263,000. Finally, Renaissance Technologies LLC bought a new position in Lisata Therapeutics in the third quarter worth about $467,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.